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Abstract The hereditary cerebellar ataxias are a diverse
group of neurodegenerative disorders primarily character-
ised by loss of balance and coordination due to dysfunction
of the cerebellum and its associated pathways. Although
many genetic mutations causing inherited cerebellar ataxia
have been identified, a significant percentage of patients
remain whose cause is unknown. The transient receptor
potential (TRP) family member TRPC3 is a non-selective
cation channel linked to key signalling pathways that are
affected in cerebellar ataxia. Furthermore, genetic mouse
models of TRPC3 dysfunction display cerebellar ataxia,
making the TRPC3 gene an excellent candidate for
screening ataxic patients with unknown genetic aetiology.
Here, we report a genetic screen for TRPC3 mutations in a
cohort of 98 patients with genetically undefined late-onset
cerebellar ataxia and further ten patients with undefined
episodic ataxia. We identified a number of variants but no
causative mutations in TRPC3. Our findings suggest that
mutations in TRPC3 do not significantly contribute to the
cause of late-onset and episodic human cerebellar ataxias.
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Introduction
The hereditary ataxias are a clinically and genetically
heterogeneous group of inherited neurodegenerative disor-
ders with ataxia as the predominant symptom. The
hereditary ataxias include the autosomal recessive atax-
ias, the dominantly inherited spinocerebellar ataxias
(SCA) and episodic ataxias (EA) and the X-linked
ataxias [12]. Although the causative mutations have been
identified in a number of ataxia subtypes, the underlying
genetic defects for many forms of hereditary ataxia remain
unknown.
The transient receptor potential (TRP) channel family
member TRPC3 is a non-selective cation channel, which is
highly enriched in the Purkinje cells of the cerebellum [2,
8]. TRPC3 is a key mediator of metabotropic glutamate
receptor (mGluR)-dependent synaptic transmission in the
Purkinje cells [8] and has also been implicated in cerebellar
development [2, 10]. Interestingly, TRPC3 is associated
with several proteins that are linked to human cerebellar
ataxia, including mGluR1, the IP3 receptor and protein
kinase C γ (PKCγ) [8, 14]. In vitro studies have shown that
TRPC3 is a substrate of PKCγ, and that mutants of PKCγ-
causing SCA14 fail to phosphorylate TRPC3, resulting in
dysfunctional calcium homeostasis [1]. Furthermore, in a
mouse model of SCA1, TRPC3 is downregulated before
the onset of degeneration [11]. Notably, genetic mouse
models of TRPC3 dysfunction exhibit cerebellar ataxia [2,
8]. Collectively, these studies point to an important role of
TRPC3 in the pathways leading to cerebellar ataxia in
mice and humans and suggest TRPC3 as a promising
candidate gene for hereditary forms of human cerebellar
ataxia.
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Here, we report a mutation screen of the human TRPC3
gene in a cohort of 108 patients with suspected but, as yet,
undetermined genetic forms of ataxia.
Subjects and Methods
Subjects
Ninety-eight samples were from patients with late-onset
cerebellar ataxia seen at a large tertiary referral centre. Patients
had sporadic onset or did not have a clearly defined family
history of ataxia. Evaluation was performed for acquired and
hereditary causes of late-onset cerebellar ataxia according to
established clinical protocols [7], and patients did not have a
defined genetic diagnosis at the time of screening. Prior
genetic analysis was performed individually based on
phenotype but, in general, minimal analysis included screen-
ing for SCA1, SCA2, SCA3, SCA6, SCA7 and FXN repeat
expansions. Patient consent was obtained and DNA was
extracted from peripheral blood leukocytes using the Gentra
Puregene Blood Kit (Qiagen). All human subject research
protocols were approved by the UCLA Institutional Review
Board and comply with the current laws of the United States.
DNA samples from ten individuals with clinical features
consistent with episodic ataxia type 2 (EA2) were obtained
with informed consent. These patients had been previously
sequenced for mutations in the coding and flanking intronic
regions ofCACNA1A and no disease-causing mutations were
identified. Ethical approval was obtained from the UCLH
ethics committee. DNA from 96 healthy adults (European
Collection of Cell Cultures) were screened as controls.
TRPC3 Sequence Analysis
Patient genomicDNA extracted from bloodwas amplified using
standard PCR techniques with primers for all coding regions of
TRPC3 (exons 1–11 of the TRPC3-001 transcript according to
the Ensembl genome browser 58) and an average of 80
nucleotides of flanking intronic regions. All amplicons were
sequenced using Big Dye 3.1 dideoxy terminator methods
(Applied Biosystems) using the amplification primers. To
confirm sequence variants, the original DNA stocks were re-
amplified and re-sequenced. Sequence analysis was performed
using 4Peaks software (Mekentosj B.V.). Exonic splicing
enhancer (ESE) motifs were predicted using ESEfinder 3.0
(Cold Spring Harbor Laboratory) and RESCUE-ESE [6].
Results
To identify possible mutations in TRPC3, we screened all 11
coding exons and flanking exon/intron boundaries of this
gene in 98 patients with undiagnosed late-onset cerebellar
ataxia. Previous work in mice had suggested that TRPC3
mutations cause a dominant pure cerebellar phenotype [2],
Table 2 Identified genetic variants in TRPC3
RefSNP Variation Exon AA change Genotype frequency Genotype frequency in population
rs13121031 c.78C>G 1 p.Ala26Ala 0.148 (G/C) 0.183 (G/C)
c.585G>A 1 p.Lys195Lys 0.009 (C/T) n/a
rs11732666 c.2199G>A 8 p.Arg733Arg 0.352 (C/T) 0.5 (C/T)
0.111 (T/T) 0.1 (T/T)
c.2271A>G 9 p.Ser757Ser 0.009 (T/C) n/a
rs61741700 c.2451A>G 10 p.Glu817Glu 0.019 (C/T) n/a
Nomenclature is based on the National Center for Biotechnology Information (NCBI) reference sequences NM_003305.2 (mRNA) and
NP_003296.1 (protein). SNP reference numbers, genetic variants and population frequency (HapMap-CEU) are listed according to the NCBI
dbSNP database. Newly identified variants are indicated in bold
n/a not applicable
Table 1 Characteristics of the patient populations studied
Number Age at exam (years) Female (%) Cerebellar only (%) SCA-like (%) Spasticity (%) Episodic (%) MSA-like (%)
98 55.5±15.8 57.1 28.6 37.8 12.2 8.2 13.3
10 25±14 33.3 0 0 0 100 0
Ninety-eight patients presented with late-onset gait and appendicular ataxia. Additional phenotypic features include involvement of
spinocerebellar pathways and/or peripheral neuropathy (SCA-like), increased lower and/or upper extremity tone (spasticity), fluctuating periods
of ataxia (episodic) or autonomic neuropathy and/or parkinsonism not diagnostic for multiple system atrophy (MSA-like). A further panel of ten
patients presented with episodic ataxia clinically similar to EA2
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therefore patients with similar phenotypes were selected
from a population of undiagnosed ataxia cases at a large
tertiary referral centre. The characteristics of this patient
population are shown in Table 1. Late-onset cases (onset
greater than age 25 years) were chosen as this is the most
common presentation of a dominantly inherited cerebellar
ataxia [13].
As TRPC3 is an ion channel, it is possible that the
human phenotype may demonstrate a paroxysmal course
[9]. Accordingly, we investigated whether TRPC3 plays a
role in episodic ataxia. We included an additional ten
samples from patients with a dominant history of episodic
ataxia whose clinical features were most consistent with
EA2 in terms of attack precipitants and duration, interictal
signs and response to acetazolamide. All ten individuals
were initially sequenced for mutations in the CACNA1A
gene and found to be negative.
Three known single nucleotide polymorphisms (SNPs)
were found in the patient cohort at similar frequencies as
published for the HapMap-CEU control population
(Table 2). In addition, we identified two novel variants
(c.585G>A, c.2271A>G), each in a single patient (Table 2).
Both of these SNPs result in synonymous changes at the
protein level (p.Lys195Lys, p.Ser757Ser). The novel variants
were not found in healthy controls. Interestingly, the
c.2271A>G variant in exon 9, which was found in a patient
with a complex phenotype of intermittent ataxia and episodic
hemiplegia, is predicted to weaken an ESE motif according
to bioinformatics calculation. The mutation was also detected
in the proband’s mother, who had hemiplegic migraine. In an
in vitro splicing assay, this putative ESE motif did not have an
effect on the splicing of an artificial minigene construct (data
not shown). However, this does not rule out the potential
importance of this ESE motif for splicing of the full TRPC3
gene in vivo in the patient’s nervous system. Unfortunately,
this patient was lost to follow-up and material was not
available for further splicing analysis.
Discussion
Genetic mouse models of loss of TRPC3 or dysfunctional
TRPC3 result in an ataxic phenotype [2, 8]. Furthermore,
several studies have linked TRPC3 to key signalling
pathways that are affected in human cerebellar ataxia [1,
14]. TRP family member genes have recently been
implicated in human neurological diseases [4, 5]. We,
therefore, hypothesized that mutations in the TRPC3 gene
might underlie previously undiagnosed late-onset forms of
human cerebellar ataxia or episodic ataxia. Our findings
suggest that mutations in TRPC3 are not a common cause
of late-onset or episodic cerebellar ataxia. We did identify a
novel variant in one patient with episodic ataxia that is
predicted to alter splicing of the TRPC3 gene. Missplicing
of exon 9 would lead to a truncated TRPC3 protein missing
important protein–protein interaction motifs in the intracel-
lular C-terminus, including the CRIB and CaM binding
domains [15]. As a consequence, this shorter form of
TRPC3 could act as a dominant negative and impair proper
calcium handling in Purkinje cells of the cerebellum.
Despite the absence of TRPC3 mutations in our group of
patients, TRPC3 mutations may still contribute to human
disease, as it is well-known that genetic mutations do not
always produce equivalent phenotypes in mice and humans
[3]. Interestingly, TRP gene mutations have recently been
associated with human neurological disease [5]. Therefore,
future genetic studies in larger patient cohorts and/or
different ethnic/geographic populations, as well as in
patients with different subtypes of cerebellar ataxia, are
necessary to fully elucidate the role TRPC3 may play in
human cerebellar ataxia.
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